ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2022

1:00PM-3:00PM: Abstract Number: 1412

Coronary Microvascular Dysfunction in Patients with Rheumatoid Arthritis and Diabetes Mellitus: A Cross-sectional Study with 13NH3 Myocardial PET/CT

RA – Diagnosis, Manifestations, and Outcomes Poster III

1:00PM-3:00PM: Abstract Number: 1540

Correlations of Soluble Interleukin-2 Receptor Serum Levels with Markers of Inflammation and Pathological High-sensitivity Troponin T and Its Possible Role as a Predictor of Early Clinical Progress in Systemic Sclerosis

Systemic Sclerosis and Related Disorders – Clinical Poster II

1:00PM-3:00PM: Abstract Number: 1424

Cost-Effectiveness of a Progressive Spacing of Tocilizumab or Abatacept in Patients with Rheumatoid Arthritis in Sustained Remission: A Medico-Economic Analysis of the ToLEDo Trial

RA – Treatment Poster III

1:00PM-3:00PM: Abstract Number: 1312

Cost-Effectiveness of Sequential Treatment with Abaloparatide Followed by Alendronate in US Men at High Risk of Fracture

Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Poster

1:00PM-3:00PM: Abstract Number: 1328

CT Evaluation of Bone Fragility 2 Years After Bariatric Surgery in Patients with Obesity: An Observational Study

Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Poster

1:00PM-3:00PM: Abstract Number: 1538

Decreased Prevalence of Autoimmune Connective Tissue Diseases in Type 1 and Type 2 Diabetes

Systemic Sclerosis and Related Disorders – Clinical Poster II

1:00PM-3:00PM: Abstract Number: 1180

Deficiency and Altered Phenotype of Mucosal-associated Invariant T Cells in Systemic Sclerosis

Systemic Sclerosis and Related Disorders – Basic Science Poster

1:00PM-3:00PM: Abstract Number: 1451

Delayed Sleep Phase Syndrome Characterizes Circadian Disorder in Patients with Active SLE

SLE – Diagnosis, Manifestations, and Outcomes Poster II: Manifestations

1:00PM-3:00PM: Abstract Number: 1481

Dementia in Adults with Systemic Lupus Erythematosus 65 Years of Age and Above: A National Administrative Claims Data Analysis

SLE – Diagnosis, Manifestations, and Outcomes Poster II: Manifestations

1:00PM-3:00PM: Abstract Number: 1486

Derivation and Internal Validation of a Disease-specific Cardiovascular Risk Prediction Model for Patients with Psoriatic Arthritis and Psoriasis

Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster III

1:00PM-3:00PM: Abstract Number: 1168

Dermal Fibroblast-derived Exosomes Drive Profibrotic Macrophage Activation in Systemic Sclerosis

Systemic Sclerosis and Related Disorders – Basic Science Poster

1:00PM-3:00PM: Abstract Number: 1494

Determinants of Clinically Important Worsening in Early Axial Spondyloarthritis: Analysis of the DESIR Cohort over 5 Years

Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster III

1:00PM-3:00PM: Abstract Number: 1366

Developing a Mobile App to Facilitate Disease Activity Assessment in Localized Scleroderma

Pediatric Rheumatology – Clinical Poster II: Connective Tissue Disease

1:00PM-3:00PM: Abstract Number: 1526

Developing a Screening Tool for the Detection of Interstitial Lung Disease in Systemic Sclerosis: The ILD-RISC Risk Score

Systemic Sclerosis and Related Disorders – Clinical Poster II

1:00PM-3:00PM: Abstract Number: 1291

Development and Pilot Implementation of a Predictive Model to Identify Visits Appropriate for Telehealth

Measures and Measurement of Healthcare Quality Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].